China’s Taibang Biologic Group has raised $300 million in a new funding round led by sovereign wealth funds Abu Dhabi Investment Authority (ADIA) and Singapore’s GIC, according to a company statement.
ADIA invested in Taibang Biologic through its subsidiary Platinum Orchid.
